Search Results - "MacKay, Helen J"

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy by León-Castillo, Alicia, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda R, Mackay, Helen J, Leary, Alexandra, Nijman, Hans W, Singh, Naveena, Pollock, Pamela M, Bessette, Paul, Fyles, Anthony, Haie-Meder, Christine, Smit, Vincent T H B M, Edmondson, Richard J, Putter, Hein, Kitchener, Henry C, Crosbie, Emma J, de Bruyn, Marco, Nout, Remi A, Horeweg, Nanda, Creutzberg, Carien L, Bosse, Tjalling

“…The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of…”
Get full text

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology by Bartley, Angela N, Washington, Mary Kay, Colasacco, Carol, Ventura, Christina B, Ismaila, Nofisat, Benson, 3rd, Al B, Carrato, Alfredo, Gulley, Margaret L, Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J, Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A

“…Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with…”
Get full text

Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type by Witkowski, Leora, Carrot-Zhang, Jian, Albrecht, Steffen, Fahiminiya, Somayyeh, Hamel, Nancy, Tomiak, Eva, Grynspan, David, Saloustros, Emmanouil, Nadaf, Javad, Rivera, Barbara, Gilpin, Catherine, Castellsagué, Ester, Silva-Smith, Rachel, Plourde, François, Wu, Mona, Saskin, Avi, Arseneault, Madeleine, Karabakhtsian, Rouzan G, Reilly, Elizabeth A, Ueland, Frederick R, Margiolaki, Anna, Pavlakis, Kitty, Castellino, Sharon M, Lamovec, Janez, Mackay, Helen J, Roth, Lawrence M, Ulbright, Thomas M, Bender, Tracey A, Georgoulias, Vassilis, Longy, Michel, Berchuck, Andrew, Tischkowitz, Marc, Nagel, Inga, Siebert, Reiner, Stewart, Colin J R, Arseneau, Jocelyne, McCluggage, W Glenn, Clarke, Blaise A, Riazalhosseini, Yasser, Hasselblatt, Martin, Majewski, Jacek, Foulkes, William D

“…William Foulkes and colleagues identify germline inactivating mutations in familial cases of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)…”
Get full text

Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1 by Fang, Ling, Du, William W., Lyu, Juanjuan, Dong, Jun, Zhang, Chao, Yang, Weining, He, Alina, Kwok, Yat Sze Sheila, Ma, Jian, Wu, Nan, Li, Feiya, Awan, Faryal Mehwish, He, Chengyan, Yang, Bing L., Peng, Chun, MacKay, Helen J., Yee, Albert J., Yang, Burton B.

“…TP53 mutations occur in many different types of cancers that produce mutant p53 proteins. The mutant p53 proteins have lost wild-type p53 activity and gained…”
Get full text

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group by OZA, Amit M, ELIT, Laurie, MACKAY, Helen J, MAZURKA, John, SEDERIAS, Joana, IVY, Percy, DANCEY, Janet E, EISENHAUER, Elizabeth A, TSAO, Ming-Sound, KAMEL-REID, Suzanne, BIAGI, Jim, PROVENCHER, Diane Michele, GOTLIEB, Walter H, HOSKINS, Paul J, GHATAGE, Prafull, TONKIN, Katia S

“…Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of…”
Get full text

Treatment of metastatic cervical cancer: Future directions involving targeted agents by Diaz-Padilla, Ivan, Monk, Bradley J, Mackay, Helen J, Oaknin, Ana

“…Abstract Cervical cancer is the third most common cause of female cancer mortality, and it remains a major health problem in populations with limited economic…”
Get full text

Pan-Canadian Analysis of Practice Patterns in Small Cell Carcinoma of the Cervix: Insights from a Multidisciplinary Survey by Fan, Kevin Yijun, Chehade, Rania, Wang, Andrew Yuanbo, Sachdeva, Anjali, MacKay, Helen J, Taggar, Amandeep S

“…Small-cell neuroendocrine carcinoma of the cervix (SCNECC) is a rare cancer with poor prognosis, with limited data to guide its treatment. The objective of…”
Get full text

Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors by APPLETON, Kim, MACKAY, Helen J, TANG, Adrian, BELLENGER, Katharine, MACKAY, Lynsay, SETANOIANS, Albert, SCHÄTZLEIN, Andreas, TWELVES, Chris, KAYE, Stanley B, BROWN, Robert, JUDSON, Ian, PLUMB, Jane A, MCCORMICK, Carol, STRATHDEE, Gordon, LEE, Chooi, BARRETT, Sophie, READE, Sarah, JADAYEL, Dalal

“…The DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (decitabine) induces DNA demethylation and re-expression of epigenetically silenced genes, and…”
Get full text

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative by Stelloo, Ellen, Bosse, Tjalling, Nout, Remi A, MacKay, Helen J, Church, David N, Nijman, Hans W, Leary, Alexandra, Edmondson, Richard J, Powell, Melanie E, Crosbie, Emma J, Kitchener, Henry C, Mileshkin, Linda, Pollock, Pamela M, Smit, Vincent T, Creutzberg, Carien L

Get full text

Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review by Komorowski, Adam S., MacKay, Helen J., Pezo, Rossanna C.

“…Background Clinical trial reports often emphasize efficacy over harms, leading to misinterpretation of the risk‐to‐benefit ratio of new therapies. Clear and…”
Get full text

Recent and current Phase II clinical trials in endometrial cancer: review of the state of art by Lheureux, Stephanie, Wilson, Michelle, Mackay, Helen J

“…Endometrial cancer (EC) is the most common gynecological cancer in the developed world. For women with advanced or high-risk disease, survival has remained…”
Get more information

Endometrial cancer: Not your grandmother's cancer by McAlpine, Jessica N., Temkin, Sarah M., Mackay, Helen J.

“…Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe…”
Get full text

Endocrine therapy in endometrial cancer: An old dog with new tricks by Jerzak, Katarzyna J., Duska, Linda, MacKay, Helen J.

“…One of the most prevalent potential therapeutic targets for women with endometrioid endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor…”
Get full text

Targeting the protein kinase C family: are we there yet? by Twelves, Christopher J, Mackay, Helen J

“…Protein kinase C (PKC) comprises a family of serine/threonine kinases that are involved in the transduction of signals for cell proliferation, differentiation,…”
Get full text

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative by Stelloo, Ellen, Bosse, Tjalling, Nout, Remi A, MacKay, Helen J, Church, David N, Nijman, Hans W, Leary, Alexandra, Edmondson, Richard J, Powell, Melanie E, Crosbie, Emma J, Kitchener, Henry C, Mileshkin, Linda, Pollock, Pamela M, Smit, Vincent T, Creutzberg, Carien L

“…This study aimed to investigate whether molecular analysis can be used to refine risk assessment, direct adjuvant therapy, and identify actionable alterations…”
Get full text

Intraperitoneal chemotherapy: Hot, timely, and relevant? by Mackay, Helen J., Kohn, Elise C.

“…The use of hyperthermic intraperitoneal chemotherapy has been growing in popularity in recent years. Even with a positive randomized trial, issues concerning…”
Get full text

Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer by Moffat, Gordon Taylor, Kong, Weidong, MacKay, Helen J., McGee, Jacob, Booth, Christopher M., Ethier, Josee-Lyne

“…The addition of bevacizumab to chemotherapy for platinum-resistant (PL-R) ovarian cancer (OC) improved progression-free (PFS) but not overall survival (OS) in…”
Get full text

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry by Vermij, Lisa, Jobsen, Jan J., León-Castillo, Alicia, Brinkhuis, Mariel, Roothaan, Suzan, Powell, Melanie E., de Boer, Stephanie M., Khaw, Pearly, Mileshkin, Linda R., Fyles, Anthony, Leary, Alexandra, Genestie, Catherine, Jürgenliemk-Schulz, Ina M., Crosbie, Emma J., Mackay, Helen J., Nijman, Hans. W., Nout, Remi A., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling

“…Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone…”
Get full text

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology by Bartley, Angela N, Washington, Mary Kay, Ventura, Christina B, Ismaila, Nofisat, Colasacco, Carol, Benson, 3rd, Al B, Carrato, Alfredo, Gulley, Margaret L, Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J, Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A

“…- ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced…”
Get full text

Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? by Komorowski, Adam S., Warner, Ellen, MacKay, Helen J., Sahgal, Arjun, Pritchard, Kathleen I., Jerzak, Katarzyna J.

“…Current National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines recommend against screening breast cancer patients for…”
Get full text